Cardinal Health CAH
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Cardinal Health (CAH) Business Model and Operations Summary
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Key Insights
Cardinal Health (CAH) Core Market Data and Business Metrics
Latest Closing Price
$164.93Market Cap
$40.10 BillionAverage Daily Volume
2,481,319 Shares52-Week Range
$93.17-$168.17Total Outstanding Shares
238.68 Million SharesCEO
Jason M. HollarTotal Employees
48,900Current Dividend
$0.51 Per Share QuarterlyIPO Date
August 4, 1983SIC Description
Wholesale-drugs, Proprietaries & Druggists' SundriesHeadquarters
7000 Cardinal Place, Dublin, OH, 43017
Earnings Reports
Expected vs. Actual Quarterly Earnings-Per-Share & Revenue
Short Volume
Daily short volume activity identifies short-term trading pressure and potential price volatility
Short Interest
Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential
Revenue Breakdown
Distribution of revenue across unique business segments & geographies
Cash Flow Statement
April 1, 2024 to March 31, 2025
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-3.80 Billion |
| Exchange Gains/Losses | $-1 Million |
| Net Cash Flow From Operating Activities | $2.95 Billion |
| Net Cash Flow From Operating Activities, Continuing | $2.95 Billion |
| Net Cash Flow From Investing Activities | $-3.80 Billion |
| Net Cash Flow, Continuing | $-419 Million |
Income Statement
April 1, 2024 to March 31, 2025
| Metric | Value |
|---|---|
| Operating Income/Loss | $2.25 Billion |
| Net Income/Loss Available To Common Stockholders, Basic | $1.56 Billion |
| Basic Average Shares | $242 Million |
| Operating Expenses | $5.60 Billion |
| Net Income/Loss Attributable To Noncontrolling Interest | $2 Million |
| Net Income/Loss Attributable To Parent | $1.56 Billion |
Comprehensive Income
April 1, 2024 to March 31, 2025
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $1.54 Billion |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $2 Million |
| Other Comprehensive Income/Loss | $-16 Million |
| Comprehensive Income/Loss Attributable To Parent | $1.54 Billion |
| Other Comprehensive Income/Loss Attributable To Parent | $-16 Million |
Balance Sheet
April 1, 2024 to March 31, 2025
| Metric | Value |
|---|---|
| Current Liabilities | $36.66 Billion |
| Accounts Receivable | $12.67 Billion |
| Equity Attributable To Noncontrolling Interest | $1.05 Billion |
| Noncurrent Assets | $15.28 Billion |
| Current Assets | $34.59 Billion |
| Liabilities And Equity | $49.87 Billion |
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |